Login
Companies $NAGE
$1.96 -$0.05 (2.49%) After hours
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc.

niagenbioscience.com

What Do They Do?

Sells finished dietary supplements under the Tru Niagen brand to consumers, plus Niagen ingredients to consumer-product manufacturers and compounding facilities.

How Do They Make Money?

Consumers and distributors buy finished supplements, while manufacturers and compounding facilities buy Niagen ingredients; product sales are counted when goods ship, and research services as they are performed.

revenue
SegmentShareRevenue
Consumer Products segment
Sold outright

75%
FY2022: 83%
Ingredients segment
Sold outright

22%
FY2022: 12%
Analytical Reference Standards and Services segment
2.4%
FY2022: 4.5%

Who Are Their Customers?

Consumers can buy Tru Niagen directly through the company site or online marketplaces, or from retailers and healthcare-practitioner resellers; ingredient sales go to manufacturers and compounding facilities through commercial partnerships.

Do Revenues Turn Into Profits?

Yes. It kept 13 cents of every revenue dollar as net income in FY2025.

Operating income, FY2025
13% of revenue
▲ +111% vs FY2024 ($7.7M, 8%)
Net income, FY2025
13% of revenue
▲ +103% vs FY2024 ($8.6M, 9%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −20%
vs $34M in Q3 FY2025
Net income
▼ Turned to a loss
vs $4.6M in Q3 FY2025
Consumer Products segment share of revenue vs 76.6% in Q3 FY2025
  • Aug 4, 2026 Company expects e-commerce business to grow 10% to 15%
  • May 6, 2026 Company sold standards business and lowered expense outlook The sale to LGC Standards was completed; expected general and administrative expense growth fell to $3–$4 million from $4–$5 million.

Growing. Revenue grew 92% in 4 years, from $67.4M in FY2021 to $129.4M in FY2025, about 18% a year.

Exit from reference standards The older report describes an analytical standards and services business; the latest report says the company agreed to sell that segment.

Pharmaceutical-grade products The latest report adds pharmaceutical-grade Niagen for compounding facilities and Niagen Plus products, alongside the older report's ingredient sales to partners.

Revenue over time
Consumer Products segment Ingredients segment Analytical Reference Standards and Services segment Pharmaceuticals segment
$200M$100M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support